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ABSTRACT
Aims: Recent studies have observed that cells from high-grade glial tumors 
are capable of assuming an endothelial phenotype and genotype, a process termed 
‘vasculogenic mimicry’ (VM). Here we model and manipulate VM in dynamic 
3-dimensional (3D) glioma cultures. Methods: The Rotary Cell Culture System (RCCS) 
was used to derive large macroscopic glioma aggregates, which were sectioned for 
immunohistochemistry and RNA extracted prior to angiogenic array-PCR. Results: A 
3D cell culture induced microenvironment (containing only glial cells) is sufficient to 
promote expression of the endothelial markers CD105, CD31 and vWF in a proportion 
of glioma aggregates in vitro. Many pro-angiogenic genes were upregulated in glioma 
aggregates and in primary explants and glioma cells were capable of forming tubular-
like 3D structures under endothelial-promoting conditions. Competitive inhibition of 
either vascular endothelial growth factor or fibroblast growth factor receptor was 
sufficient to impair VM and downregulate the tumor-derived angiogenic response, 
whilst impairing tumor cell derived tubule formation. Glioma xenografts using the 
same cells reveal tumor-derived vessel-like structures near necrotic areas, consistent 
with widespread tumor-derived endothelial expression in primary glioma tissue. 
Conclusions: Our findings support studies indicating that tumor-derived endothelial 
cells arise in gliomas and describe a dynamic 3D culture as a bona fide model to 
interrogate the molecular basis of this phenomenon in vitro. Resistance to current 
anti-angiogenic therapies and the contribution of tumor derived endothelial cells to 
such resistance are amenable to study using the RCCS.
INTRODUCTION
The rationale for current anti-angiogenic strategies 
in high-grade glioma is based upon the targeting of 
endothelial cells that are recruited from surrounding 
vascular networks or induced via sprouting of pre-existing 
vessels. Vascular endothelial growth factor (VEGF), a 
canonical master regulator of angiogenesis, has been 
regarded as a common effector of several angiogenic 
pathways and the anti-VEGF monoclonal antibody 
bevacizumab (Avastin) is one of few agents to progress 
to phase III trials. However, whilst the phase II clinical 
results of VEGF blockade in patients were promising [1, 
2], the outcomes of phase III trials have been disappointing 
with no benefit to overall survival [3, 4]. The assumption 
of a genetically stable endothelial phenotype in GBM has 
recently been challenged with evidence of tumor-derived 
endothelial cells (TDEC), which differ from but can 
integrate with recruited endothelial cells [5-7]. TDEC are 
genetically dysregulated cells, which derive from a process 
intrinsic to the tumor cell termed ‘vasculogenic mimicry’ 
(VM) [8]. VM was initially described in melanoma but has 
been observed in leukemia and several solid neoplasms 
including prostate cancer and glioblastoma (GBM) [9-
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11]. VM-derived vessels constitute extracellular matrix 
(ECM)-rich networks lined by tumor cells. Xenografts 
of human GBM cell lines in rodents were demonstrated 
to develop blood vessels with human specific endothelial 
epitopes, harboring tumor specific molecular changes such 
as epidermal growth factor receptor (EGFR) amplification. 
Further investigation of VM and the processes that 
control this cellular behavior [12] will be greatly aided 
by an ability to simulate this process in vitro without the 
need for an artificial ECM substrate, which will lead to a 
more comprehensive understanding of the environmental 
conditions and molecular pathways that promote the 
adoption of this strategy by cancer cells.
There is a growing recognition conceptually that 
three-dimensional (3D) culture technologies may more 
accurately reflect tumor pathophysiology and recapitulate 
the in vivo tumor microenvironment in vitro, particularly 
for complex processes such as VM. One method of 
generating 3D aggregates in a non-turbulent environment 
where cells secrete endogenous ECM and growth 
factors is the Rotary Cell Culture System (RCCS™), 
originally developed by the National Aeronautics and 
Space Administration (NASA) to study the effects of 
microgravity on cells and tissues [13]. We have previously 
demonstrated that the RCCS can recapitulate brain tumor 
molecular heterogeneity and the hypoxic gradient of 
primary brain tumors [14]. Here we investigate whether the 
VM process and the glioma-derived angiogenic response 
can be characterized and manipulated in the RCCS, thus 
presenting a model for in vitro pharmacological studies 
aimed at disrupting this potentially important component 
of tumor growth.
RESULTS
High-grade glioma (HGG) and ependymoma 
cells express endothelial markers in dynamic 3D 
culture
We hypothesized that RCCS culture would induce 
endothelial-like protein expression in glioma cells in the 
absence of any endothelial cells or endothelial-promoting 
media. Primary HGG explant tissue exhibited distinct 
expression of the immature endothelial marker CD105 
(endoglin) (Figure 1A) in blood vessel structures within 
7-10 days growth within the RCCS. We have shown here 
and previously [14] that macroscopic RCCS aggregates 
(~0.5 cm – 0.75 cm diameter) can generate intrinsic 
hypoxic gradients whereby hypoxic glioma cells with 
low proliferative activity arise in peri-necrotic regions 
surrounding the aggregate core (Figure 1B). Cells 
at the interface between the hypoxic core and viable 
proliferative rim of aggregates expressed the endothelial 
cell membranous marker CD105 in RCCS 3D tumor-only 
cultures of the primary cell line GB-1 and in KNS42 and 
U87 cell line-derived HGG aggregates (Figure 1C-1E).
A marked proportion of CD105 positive cells 
were also co-positive for GFAP (Figure 1F). Co-staining 
of CD105 / HIF-2α (a marker of hypoxic adaptation) 
demonstrated co-localization in the core region (hypoxic 
and necrotic area) of U87 aggregates (Figure 1G and 
Supplementary Figure 1A for wide-field view of whole 
RCCS aggregate). KNS42 RCCS aggregates additionally 
exhibited high levels of the endothelial marker vWF, with 
positive cells typically located at the rim / core interface 
regions (Figure 1H). 
Tumor-derived endothelial marker expression was 
not restricted to GBM cells as aggregates of the primary 
ependymoma cell line Res196 also exhibited CD105 
expression (Figure 1I). Neither CD105 nor CD31 was 
expressed in KNS42 or U87 2D monolayer cells after 72 
hours culture (Supplementary Figure 2A-2D). Prominent 
expression of the mature endothelial marker CD31 was 
observed surrounding tubular-like structures in U87 
aggregates (Figure 1J and Supplementary Figure 1B for 
wide-field view of whole RCCS aggregate), which were 
yet distinct from canonical vessels surrounded by GFAP 
positive tumour cells in primary HGG tissue. Collectively 
these findings indicate that a 3D-induced tumour 
microenvironment is sufficient to promote expression 
of the endothelial markers CD105, CD31 and vWF in a 
proportion of high grade glioma and ependymoma cells 
that reside in distinct tumour aggregate regions.
Tumor-derived angiogenic response in the RCCS 
better recapitulates primary glioma angiogenic 
expression profiles
Array quantitative RT-PCR performed for 84 
angiogenesis-related genes revealed that KNS42 and U87 
GBM RCCS aggregates exhibited significant upregulation 
of many angiogenic genes relative to corresponding 
monolayer cultures including FGF1, VEGFR1, VEGFC, 
ANGPT1, CD31, HGF, CXCL9, TGFβR1 and IGF1 (p 
< 0.001), whilst THBS1, an anti-angiogenic mediator 
was downregulated (p < 0.001) (Figure 2A-2B and 
Supplementary Tables 1 and 2). GB-1 HGG aggregates 
showed significant upregulation of four genes including 
FGF2 and ANGPT1 (p < 0.001), though many more 
genes were upregulated but did not achieve statistical 
significance (Figure 2C-2D). To determine the resemblance 
to angiogenic response in primary tumors, GB-1 RCCS 
aggregates and monolayer cultures were analyzed in 
comparison to the primary grade III glioma from which 
the cells were derived. All genes were significantly down-
regulated in 2D culture relative to the parental tumor, 
with the most differentially expressed markers including 
CD105, NRP1, FGFR3 and MMP2 (p < 0.005) (Figure 
2E). Although many genes were downregulated in GB-1 
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3D culture relative to the parental tumor (e.g. FGFR3, 
TGFβ1 and TYMP), certain genes were now upregulated 
(e.g. FGF2, ANGPT1 and EFNA3). Additional genes 
were upregulated but did not achieve significance and 
the overall pattern of angiogenic-related expression was 
more similar between 3D culture and parental tumor than 
between 2D culture and tumor (Figure 2F). Angiogenic 
gene expression was further compared between an 
adult GBM (T7/11) acquired directly from surgery and 
cultured as explant tissue in the RCCS and a monolayer 
culture derived from this tumor (passage 6). Significant 
upregulation of many angiogenic genes including 
MMP9, CXCL3, IL6 and IL8 (p < 0.005) and significant 
downregulation of the anti-angiogenic genes THBS1 and 
THBS2 (p < 0.001) was observed in the explant compared 
to the monolayer, providing direct evidence that loss of 
Figure 1: Vascular gene expression in putative brain tumor-derived endothelial cells within RCCS aggregates in 
vitro. Immunological detection of CD105, CD31 and vWF endothelial markers in high grade glioma 3D aggregates. A. Distinct CD105 
expression (brown) in microvessel structures in primary high-grade glioma explant tissue. B. Hypoxic regions surrounding the necrotic core 
(denoted C) of U87 aggregates are identified using Hypoxyprobe™ (brown); hypoxic staining is absent in the densely cellular peripheral rim 
(denoted R). C. GB-1 cells derived from primary high-grade glioma with membranous CD105 expression (brown) at the interface (denoted 
I) between densely cellular aggregate rim (denoted R) and necrotic core (denoted C). D. KNS42 cells with membranous CD105 expression 
(brown). E. U87 cells with membranous CD105 expression (brown). F. Co-localization of CD105 (red) with GFAP (green) in KNS42 
cells. G. U87 cells exhibit co-localization of CD105 (red) and HIF-2α (green) in aggregate cores and in localized regions. H. Widespread 
vWF expression at the interface (denoted I) between densely cellular aggregate rim (denoted R) and relatively sparser core (denoted C) of 
KNS42 cells. I. Distinct CD105 expression in aggregate core (denoted C) and rim (denoted R) regions in Res196 ependymoma aggregates. 
Two aggregates shown that have been harvested and subsequently sectioned in close proximity to each other. J. U87 cells with distinct 
CD31 expression (red) at the aggregate rim / core interface. K. Prominent CD31 expression (red) in canonical vessels surrounded by GFAP 
positive tumour cells (green) in primary HGG tissue. Scale bar A, C, E-H, J-K = 25µm; D = 10µm; B and I = 200µm. All aggregates were 
cultured for 7-10 days within the RCCS.
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3D structure was associated with a decreased angiogenic 
response in monolayers (Figure 2G and Supplementary 
Table 3). To establish any influence from brain endothelial 
cell signaling, angiogenic expression in KNS42 / HBMEC 
co-cultured tumor / endothelial aggregates were compared 
to tumor-only cultures. Many genes were downregulated 
in the co-culture including VEGFR1, NOTCH4, FGF1, 
FGF2, TGFβR1 and MMPs (p < 0.001), with a few 
genes upregulated significantly including CXCL1 and 
ID1 (Figure 2H and Supplementary Table 4), indicating 
an overall dampening of the glioma-derived angiogenic 
response in the presence of canonical brain endothelial 
cells.
Tumor-derived vascular markers are expressed in 
vivo and glioma patient tissue
To confirm that VM was a phenomenon found in 
tumor development in vivo, U87 GBM cells (at identical 
passage to that of U87 RCCS culture) were cultured 
subcutaneously as flank xenografts in nude mice. Within 
the xenografted tumor mass, blood vessels were positive 
for CD31 and CD105 protein expression using antibodies 
specific for the human CD31 and CD105 epitopes (Figure 
3A-3B respectively). Erythrocytes were observed within 
such CD105 positive vessel-like structures, indicating that 
they were connected to and forming part of the functional 
mouse vasculature. In contrast, vessels at the periphery of 
the grafts in the peri-tumoural area were negative for both 
CD31 and CD105 human protein expression (Figure 3C). 
To evaluate the contribution of VM to the peri-
vascular niche in human tumors, the co-expression of glial 
and endothelial markers was investigated in a cohort of 
primary pediatric HGG patients. A minority population of 
cells stained co-positive for the astrocytic marker GFAP 
and endothelial marker CD105 or CD31 suggesting that 
these may be TDEC within the tumor mass. Co-staining 
for GFAP / CD105 (Figure 3D-3E) was more frequent than 
co-staining for GFAP / CD31 (Figure 3F) with CD105 
positive TDEC observed in the vicinity of peri-necrotic 
areas within the tumor. 
Glioma-derived endothelial marker expression 
may recapitulate an embryonic-like process in 
vitro
We sought to examine whether non-neoplastic 
embryonic stem cells (ESC) or lineage defined neural 
Figure 2: Brain tumor-derived angiogenic expression is upregulated in RCCS culture in vitro. Volcano plots of angiogenesis 
array quantitative RT-PCR with a log2 fold difference on x-axis and p-value on y-axis. Horizontal blue line represents a p-value of 0.05 
and vertical pink lines represent a fold change of +/- three. A.-C. Angiogenic gene expression between 2D and 3D glioma cultures of 
KNS42, U87 and GB-1 respectively. D. Box plot representation of volcano plot from C., comparing gene expression of GB-1 3D versus 2D 
expression, illustrating significant upregulation of FGF2 and ANGPT1 genes in 3D culture. Each bar represents one of 84 angiogenic genes. 
E.-F. Angiogenic gene expression in GB-1 2D and 3D cultures respectively, relative to the HGG primary tumor from which the cell line 
was derived. G. Differential angiogenic gene expression in primary GBM explant tissue relative to the 2D monolayer line T7 / 11 derived 
from this explant. H. Differential angiogenic expression between KNS42 / HBMEC heterogeneous aggregates and KNS42 tumor-only 
aggregates. For all experiments, each dot represents the mean gene expression of one gene assayed in three independent RNA samples from 
three different 3D aggregates, with selected genes of interest identified on plots. Each experimental condition (e.g. 3D or 2D), is presented 
relative to each other.
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stem cells (NSC) also had the capacity under appropriate 
cell culture conditions to exhibit endothelial-like 
characteristics. A proportion of glioma cells exhibit stem-
like characteristics and we hypothesized that VM may 
be a recapitulation of a stem-like behavior lost in non-
neoplastic lineage defined cells. CD105 was expressed in a 
proportion of mouse embryonic stem cells (ESC) cultured 
as RCCS aggregates (Figure 4A), whereas CD105 was 
completely absent in neural stem cells (NSC) derived from 
post-natal mice and cultured in the RCCS (Figure 4B). 
Neural stem cells express three out of four genes required 
to form a pluripotent cell [21]; the remaining gene encodes 
the transcription factor OCT4, which has been recently 
implicated as a potential oncogene [22]. Interestingly, 
when OCT4 was constitutively over-expressed in the same 
NSC line, CD105 expression became evident in sporadic 
cells within aggregates (Figure 4C). CD31 was absent 
from all ESC and NSC aggregates (Supplementary Figure 
2E-2G). 
Tumor-derived angiogenic expression is 
downregulated upon VEGF / FGFR inhibition in 
vitro
Based on our angiogenesis array quantitative RT-
PCR data and existing glioma angiogenesis literature 
[5, 23-25], we selected VEGF and FGFR as candidate 
mediators of the angiogenic response, observed to 
be significantly upregulated in the RCCS relative to 
Figure 3: Glioma tumor-derived endothelial marker expression in vivo. Subcutaneous human U87 flank xenografts from 
immunodeficient mice were assessed for tumor-derived endothelial marker expression. A. CD31 human epitope expression (brown stain) 
lining the wall of a vessel-like structure within the U87 xenograft. B. CD105 expression (brown stain) lining vessel-like structures within a 
xenografted tumor, containing visible erythrocytes (arrow). C. Mouse blood vessel from periphery of tumor graft containing erythrocytes 
but with no positive staining for human-specific CD105. Immunofluorescence was conducted for tumor and endothelial markers in a 
selection of pediatric HGG. D.-E. Merged image showing co-localization of CD105 (red) and GFAP (green) on putative TDEC in primary 
HGG tissue. F. Co-localization of CD31 (red) and GFAP (green) in primary HGG tissue. Scale bar A-C = 25µm; D-F = 20µm.
Figure 4: OCT4 overexpression in mouse NSC RCCS aggregates leads to CD105 expression. A. CD105 expression in mouse 
ESC (brown stain) B. CD105 expression is absent in mouse NSC. C. Sparse CD105 expression in mouse NSC with OCT4 overexpression 
(brown stain). Three independent aggregates for each experiment were fixed and sectioned, with representative images shown. Scale bar 
= 25µm. 
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monolayer cultures (Supplementary Tables 1 and 2) 
(KNS42: VEGFR2 +135-fold (p < 0.001), FGF +6.44-
fold (p < 0.001); U87: VEGFR1 +22.63-fold (p < 0.001), 
FGF2 +2.85-fold (p < 0.01). KNS42 and U87 GBM 
aggregates were exposed for three days to the VEGF 
competitive inhibitor CBO-P11 (Calbiochem), which 
blocks the binding of the VEGF ligand to its receptors 
VEGFR1 and VEGFR2 or the FGF receptor tyrosine 
kinase inhibitor PD166866 (Calbiochem), which acts 
as a competitive inhibitor of the FGF1/2 ligands. We 
verified the concentrations at which these inhibitors 
negatively affected cell viability (Supplementary Figure 
3) and on this basis selected 10 µM VEGF inhibitor and 
15 µM FGFR inhibitor as concentrations at which anti-
angiogenic phenotypes (down-regulation of angiogenic 
genes and disruption of vascular-like structures) could 
be distinguished without severe compromise to cell 
viability (Supplementary Figure 4). Many angiogenesis-
related genes were downregulated in KNS42 aggregates 
treated with either inhibitor when compared to untreated 
aggregates. Prominent amongst downregulated genes in 
response to VEGF pathway inhibition were TYMP, LEP, 
HGF, CXCL9, MMP2, VEGFR1 and ANGPT1 (p < 
0.001) (Figure 5A and Supplementary Table 5). Prominent 
KNS42 genes significantly downregulated in response 
to FGFR inhibition were TYMP, HGF, TEK, CXCL9, 
MMP9, VEGFR1, ANGPT1, FGF1 and FGF2 (p < 0.001) 
(Figure 5B and Supplementary Table 6). KNS42 CD105 
and CD31 expression was significantly reduced relative 
to untreated aggregates upon both drug treatments (p < 
0.001), though with greater fold change reductions in 
response to FGFR inhibition (-111.9 for CD31 and -90.7 
for CD105) than observed for VEGF inhibition (-30.1 for 
CD31 and -73.3 for CD105). Two KNS42 genes were 
significantly downregulated when treatment with both 
anti-FGFR and anti-VEGF agents was compared (IL6 
and CDH5) (Supplementary Tables 5-6). Similarly, many 
genes were downregulated in U87 as a response to either 
agent including growth factors and the endothelial specific 
TEK, a receptor for angiopoietin-1 known to be critical 
for normal vascular development (Figure 5C-5D). Several 
genes exhibited reduced expression in a similar manner 
to that observed for KNS42, e.g. LEP, HGF and TEK (p 
< 0.001) and many U87 cytokines were downregulated 
in response to either drug, including the pro-angiogenic 
cytokines CXCL9, CXCL6, CXCL5 and PF4 (CXCL4). 
Other notable downregulated genes included VEGFR1, 
TGFβR1, IGF1, EREG (an EGFR ligand), ANGPT1 
and HGF (p < 0.001) and remodelers of the ECM such 
as MMP9 (p < 0.001) (Figure 5C-5D and Supplementary 
Tables 7-8). CD31 was significantly downregulated 
(p < 0.001) in response to either agent (-15.08 fold for 
anti-VEGF and -11.9 fold for anti-FGFR) but CD105 
expression was not significantly altered by either drug 
in U87 aggregates. Notably, the VEGFR1 transcript 
was significantly downregulated by U87 in response to 
treatment with either drug (p < 0.001) (Supplementary 
Tables 7-8).
Vasculogenic mimicry is abrogated upon VEGF/
FGFR inhibition in vitro
Glioma aggregates treated with either the VEGF or 
FGFR inhibitor retained a similar morphologic appearance 
to untreated aggregates, with a pronounced core region 
of low cellular density relative to a peripheral rim of 
high cellular density. (Supplementary Figure 4). KNS42 
aggregates exhibited low expression of the proliferation 
marker Ki67 in response to FGFR inhibition (4% +/- 0.6), 
but retained foci of high Ki67 expression in response 
to VEGF inhibition (18% +/- 2.3) (Figure 5E-5F). U87 
aggregates exhibited an absence of actively proliferating 
Ki67 cells when FGFR was inhibited (0% +/- 0.0), but 
retained sporadic proliferating Ki67 cells when VEGF 
was inhibited (8% +/- 2.9) (Figure 5G-5H). Exposure of 
KNS42 and U87 aggregates to either inhibitor (at doses 
observed not to impair cell viability in monolayer culture, 
see Supplementary Figure 3) resulted in complete loss of 
tumor-derived CD105 and CD31 expression (Figure 6), 
when compared to untreated cells (Figure 1D-1E and 1J). 
Collectively these findings indicate that TDEC observed 
in RCCS GBM aggregates is at least in part, dependent on 
VEGF / FGFR signaling. Whereas lack of TDEC may be 
coupled to proliferation impairment upon VEGF inhibition 
in KNS42 and U87 RCCS culture, TDEC absence is 
independent of proliferation impairment upon FGFR 
inhibition.
Glioma cells form endothelial-like tubules in a 
VEGF/FGFR-dependent manner in vitro
Under 3D culture conditions (Matrigel) that 
promote an endothelial phenotype, KNS42 glioma cells 
(demonstrating an upregulated angiogenic response 
in RCCS cultures) were capable of generating distinct 
branching network structures characteristic of endothelial 
cells (Figure 7A). Branching structures were more 
pronounced under hypoxic strain, albeit the numbers 
of tubules were not significantly different (p < 0.05) to 
that observed in normoxic cultures (Figure 7B). VEGF 
inhibition resulted in mild but significant impairment to 
tubular structures, with fewer visible tubules relative to 
normoxic cultures (p < 0.05) (Figure 6C), whilst FGFR 
inhibition or dual VEGF / FGFR inhibition resulted in 
severe significant impairment of closed tubule formation 
(p < 0.01) (Figure 7D-7E). Exposure to DMSO alone did 
not lead to a significant change (p < 0.05) in branching 
network formation compared to KNS42 cells under 
normoxia (Figure 7F). 
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Figure 5: Downregulation of tumor-derived angiogenic response upon VEGF or FGFR inhibition in vitro. Volcano plots 
of angiogenesis array quantitative RT-PCR with a log2 fold difference on x-axis and p-value on y-axis. Horizontal blue line represents 
a p-value of 0.05 and vertical pink lines represent a fold change of +/- three. Each dot represents the mean gene expression of one gene 
assayed in three independent RNA samples from three different 3D aggregates, with selected genes identified on plots. A.-B. KNS42 
aggregates treated with the CBO-P11 VEGF inhibitor or PD16686 FGFR inhibitor respectively, relative to untreated KNS42 aggregates, 
showing significant downregulation of many angiogenesis-related genes in treated cells. C.-D. U87 aggregates treated with CBO-P11 and 
PD166866 relative to untreated U87 aggregates respectively, showing significant downregulation of many genes in treated aggregates. 
Angiogenic gene expression depicted represents the mean of three independent experiments each run using triplicate arrays. E. Low levels 
of active proliferation within KNS42 aggregates treated with PD16686, with 4% +/- 0.6 of Ki67 positive cells. F. Localized patches of 
actively proliferating areas within KNS42 aggregates treated with CBO-P11, with 18% +/- 2.3 of Ki67 positive cells. G. No Ki67 expression 
in any cells within U87 aggregates treated with PD16686 (0% +/- 0.0 of Ki67 positive cells). H. Sporadic expression of Ki67 within KNS42 
aggregates treated with CBO-P11, with 8% +/- 2.9 of Ki67 positive cells. Cells were counted from three independent aggregates and using 
either a whole aggregate field of view or three different field of views for each aggregate. The mean +/- SEM proportion of Ki67 positive 
cells relative to total number of cells is given and representative images shown. Scale bar E-F = 200µm; G-H = 25µm
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Figure 6: Loss of tumor-derived endothelial marker expression upon VEGF or FGFR inhibition in vitro. KNS42 and U87 
aggregates were cultured for 7 days in the RCCS and subsequently exposed to the CBO-P11 VEGF inhibitor (10 µM) or PD16686 FGFR 
inhibitor (15 µM) respectively for 3 days. A.-D. Absence of CD105 and CD31 staining upon exposure to either inhibitor in KNS42 cells. 
E.-H. Absence of CD105 and CD31 staining upon exposure to either inhibitor in U87 cells. Scale bar A-H = 200µm. Whole field views of 
aggregates are shown in all cases to indicate complete absence of endothelial marker staining.
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Tumor-derived angiogenic expression is a function 
of the 3D microenvironment in vitro
To examine whether angiogenic expression is 
exclusively a hypoxia-driven event independent of the 
RCCS, KNS42 and U87 monolayer cells were cultured 
under hypoxic conditions (1% O2) and angiogenic 
gene profiles were compared to RCCS 3D cultures and 
normoxic (21% O2) monolayer cultures. The majority of 
angiogenic-related genes did not demonstrate significantly 
upregulated expression in hypoxia monolayer culture 
relative to normoxic monolayer culture for both KNS42 
and U87 cells, whereas several genes were significantly 
Figure 7: GBM cells develop morphological features of endothelial cells when cultured under endothelial-promoting 
conditions in vitro. A. Distinct endothelial-like tubular structures comprised of KNS42 cells under normoxia (21% oxygen). B. Better 
structurally-defined tubules when hypoxia (1% hypoxia) is induced using DFO, but not significantly different in mean number (41.8 +/- 3.6) 
(p < 0.05) relative to untreated normoxic cultures (45.4 +/- 6.1). C. Moderate impairment of tubular structures upon VEGF inhibition, with 
significant reduction in mean tubule number (23.4 +/- 4.1 tubules) (p < 0.05) relative to untreated cultures. (D-E) Pronounced impairment 
of closed tubular structures and reduction of tubule number upon FGFR inhibition (9.5 +/- 3.3) (p < 0.05) and dual VEGF / FGFR inhibition 
(4.2 +/- 3.3) (p < 0.01). F. Exposure to DMSO alone (FGFR inhibitor vehicle) does not impair tubule formation with no significant 
difference in mean tubule number (47.6 +/- 8.4) (p < 0.05) relative to untreated normoxia cultures. Representative images were taken 48 
hours post-seeding and post-exposure to inhibitors. Scale bar = 50µm.
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upregulated under normoxia (p < 0.001) (Figure 8A and 
8C respectively). For both KNS42 and U87 cells, the 
majority of angiogenic-related genes were significantly 
upregulated in 3D RCCS culture relative to 2D hypoxic 
culture (p < 0.001) (Figure 8B and 8D respectively). No 
gene was significantly upregulated in U87 2D hypoxia 
culture (Figure 8D) and only ID3 was significantly 
upregulated in KNS42 2D hypoxia culture (p < 0.001) 
(Figure 7B). These findings suggest that hypoxia alone 
within the RCCS environment per se does not trigger VM 
and a tumor-derived angiogenic response in GBM cells 
in vitro.
DISCUSSION
The induced expression of the endothelial markers 
CD105, CD31 and vWF in HGG cells within the dynamic 
RCCS was typically observed at the interface between the 
necrotic core of the aggregate and highly cellular rim. As 
we have previously showed that this region is hypoxic 
but viable [14], our finding is consistent with studies 
indicating that hypoxia is a key microenvironmental cue 
promoting the microvascular niche. Furthermore, culture 
conditions promoting endothelial proliferation enhanced 
the TDEC phenotype in glioma cells with respect to 
tubular structure formation in Matrigel and which was 
Figure 8: GBM cells exhibit tumor-derived angiogenic expression as a consequence of a 3D microenvironment in vitro. 
Volcano plots of angiogenesis array quantitative RT-PCR with a log2 fold difference on x-axis and p-value on y-axis. Horizontal blue line 
represents a p-value of 0.05 and vertical pink lines represent a fold change of +/- three. Each dot represents the mean gene expression 
of one gene assayed in three independent RNA samples from three different 3D aggregates, with selected genes identified on plots. A. 
KNS42 2D monolayers cultured under hypoxia (1% O2) relative to KNS42 2D monolayers cultured under normoxia (21% O2), showing 
significant downregulation of several angiogenesis-related genes in hypoxic cells with only CDH5, TGFA, VEGFC and TEK upregulated 
under hypoxia. B. KNS42 2D monolayers cultured under hypoxia (1% O2) relative to KNS42 3D RCCS aggregates, showing significant 
downregulation of the majority of angiogenesis-related genes in hypoxic monolayers with only ID3 upregulated. C. U87 2D monolayers 
cultured under hypoxia (1% O2) relative to U87 2D monolayers cultured under normoxia (21% O2), showing significant downregulation 
of several angiogenesis-related genes in hypoxic cells with only CXCL3, S1PR1 and ITGAV upregulated under hypoxia. D. U87 2D 
monolayers cultured under hypoxia (1% O2) relative to U87 3D RCCS aggregates, showing significant downregulation of the majority of 
angiogenesis-related genes in hypoxic monolayers.
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moderately more distinct under hypoxic strain. However 
our results indicate that hypoxia alone was insufficient to 
induce VM-related and tumor-derived angiogenic changes 
in monolayer cultures, but rather that the key trigger in the 
context of our experiments was the three-dimensionality of 
the RCCS and Matrigel cultures. This implies that cellular 
interaction is an important determinant of tumor-derived 
VM in our culture systems and which may be potentiated 
by induced hypoxic strain as observed in the tubule-
forming assay. This finding is consistent with a report 
of hypoxic promotion of VM in a 3D ovarian carcinoma 
culture model [26].
We demonstrate CD105 / CD31 TDEC co-
expression and VM structures in U87 xenografts in vivo 
and CD105 / GFAP and CD31 / GFAP co-localization 
in primary HGG tissue consistent with previous studies 
[10], albeit our interpretation is limited to a flank model 
rather than orthotopic brain. This is evidence against the 
possibility that TDEC and VM are simply a function 
unique to the RCCS, but rather support the notion that 
these are distinct biological processes that may contribute 
to neo-vascularization within primary HGG tissue. The 
importance of endothelial-like cells to tumor growth may 
be best understood in the creation of stimulatory cell-
cell contacts in the peri-vascular niche, as opposed to the 
creation of a functional vasculature. This has previously 
been suggested by the observation of increased growth of 
glioma cells co-cultured with endothelial cells. We have 
previously documented that co-localization of brain tumor 
and endothelial markers frequently occurs in peri-necrotic 
regions of primary HGG and that CD105 expression is 
an indicator of poor prognosis in a cohort of pediatric 
HGG (n = 150) [27]. Our data suggests that the presence 
of necrotic cells may stimulate tumor cells to acquire a 
TDEC phenotype. Glioma cell / endothelial cell co-
cultured aggregates displayed a greatly altered pattern of 
gene expression compared to glioma-only aggregates, with 
many of the genes putatively implicated in VM including 
NOTCH4, TGFβ, HGF and CD31 being significantly 
downregulated. One explanation for this may be that 
in the presence of sufficient pre-existing endothelial 
cells there is less of a selective pressure for glioma 
cells to transdifferentiate to TDEC and undergo VM. It 
is plausible that the transdifferentiation of TDEC under 
hypoxic conditions is in part due to a lack of endothelial 
precursors with which to re-constitute the neo-vascular 
niche. Several angiogenesis-related molecules such as 
Laminin, Neuropilin-2 and CD105 have been reported 
to be enriched in glioma stem cells capable of forming 
vascular structures in vitro [8], implicating that TDEC 
transdifferentiation is facilitated by a glioma stem-like 
phenotype.
The signaling pathway(s) by which TDEC and 
VM emerge are still under investigation. We show that 
endothelial markers are expressed in ESC aggregates 
and NSC aggregates which overexpress OCT4, but not 
wild-type NSC. This finding implies that an induced 
pluripotent-like state is necessary to generate VM in 
normal lineage-restricted neural cells, whereby OCT4 
overexpression is necessary for CD105 expression in NSC. 
An association between genes linked to an undifferentiated 
embryonic-like phenotype and VM-positive tissues has 
been reported in VM studies from aggressive melanoma 
[28]. Our finding suggests that VM in brain tumor cells 
recapitulates a process that relies on pluripotent-like 
features, perhaps similar to an embryonic-like process 
that originates in the transformed neural precursor cells. 
The expression of endothelial markers in lineage defined 
NSC upon forced OCT4 expression suggests a similar 
process could potentially underlie the ability of cancer 
cells to undergo the same change, whereby some glioma 
cells under selection pressure at least transiently revert to 
a primitive glioma stem cell state, prior to exerting tumor-
derived phenotypes.
Several angiogenesis-related genes were 
upregulated within glioma RCCS cultures in comparison 
to monolayer cultures, including components of the 
FGF and TGFβ signaling pathways, suggesting that 
these factors are mediators of VM that may be targeted 
therapeutically. Indeed downregulation of TGFβ in GBM 
U251 cells abrogates the ability to form VM-associated 
tubular structures on Matrigel with an associated decline 
in MMP-2 activity [29]. The PI-3 kinase network mediated 
by MMP-2 upregulation has previously been implicated 
in melanoma VM [30], consistent with our observation 
that MMP-2 was one of the most downregulated 
genes in response to FGFR or VEGF inhibition. Other 
metalloproteinases, e.g. MMP-9, were among the genes 
most upregulated by RCCS 3D culture, consistent 
with a significant association between VM and MMP-
9 expression in clinical glioma specimens [31] and 
in tumor / endothelia co-cultures [32]. It is plausible 
therefore that VM may be associated with the aggressive 
and invasive nature of gliomas. The remodeling of ECM 
has been shown to provide the space needed for VM and 
is regulated by metalloproteinases [33]. Therefore the 
upregulation and secretion of endogenous ECM we have 
previously observed in RCCS aggregates [14], coupled 
with the upregulation of metalloproteinases shown in 
this study, suggests that ECM remodeling may precede 
VM formation and glioma-derived endothelial marker 
expression. 
Our results suggest that small molecule inhibitors 
that competitively bind to VEGF and FGFR both have 
an effect in abrogating the development of VM, though 
FGFR may have a more fundamental role. Approaches 
such as the monoclonal antibody bevacizumab that target 
free VEGF ligand may have a limited inhibitory effect on 
angiogenesis if FGFR dependent VM plays a significant 
role. Although TDEC failed to express VEGFR in one 
study, others have reported that VEGFR2 is expressed 
on these cells [5, 34]. Blockade of VEGF ligand or gene 
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silencing of VEGFR2 appears to inhibit the differentiation 
of tumor endothelial progenitors into endothelium, but not 
the differentiation of glioma stem-like cells into immature 
tumor endothelial progenitors [6]. Similarly, glioma stem-
like cells formed a higher number of vascular structures 
in a tubule-forming assay and preferentially expressed 
high levels of VEGFR2 (relative to parental GBM cells), 
which was abrogated upon targeting of VEGFR2 using 
a monoclonal antibody [35]. This finding suggests that 
the VEGF-dependent upregulated angiogenic response, 
endothelial marker expression and vascular structure 
formation observed in our study, may be due to a VEGF-
mediated role in the maturation of TDEC. As VEGF 
inhibition still resulted in a reduction of endothelial 
markers, our results also imply that the differentiation 
of a proportion of glioma cells into TDEC in the RCSS 
may be VEGF-dependent. However, branching network 
formation and gene expression of endothelial markers 
was more strongly abrogated by FGFR inhibition in our 
study, suggesting that FGF signaling may be functionally 
more relevant to glioma VM, at least in the context of our 
model. Studies concerning VM in glioma have not yet 
addressed the direct clinical significance of this process in 
the course of tumor initiation, progression and recurrence. 
Anti-angiogenic therapy trials may be required to consider 
VM as a possible mechanism of therapeutic failure, as 
TDEC often do not express the same levels of receptors 
that bona fide endothelial cells display.
The RCCS provides a practical way of modeling 
VM within a human-specific model in vitro, allowing 
for biological manipulation and investigation of this 
potentially important mechanism of resistance to anti-
angiogenic therapy. To our knowledge this is the first 
report of TDEC and VM in a 3D glioma culture model. 
The investigations presented here suggest that FGFR plays 
a significant role in VM but that VEGF, OCT4 and other 
pathways also play important roles and that the process 
is intrinsically linked to cell-to-cell interaction within 
a 3D context, hypoxia and necrosis. Pharmacological 
intervention in the RCCS in comparison to rodent 
orthotopic models will be required to further validate 
the RCCS (and indeed alternative 3D culture models) as 
a surrogate to study and therapeutically manipulate VM. 
Further work will undoubtedly reveal a more complex 
molecular basis of VM and elucidate the therapeutic 
potential of targeting VM in malignant tumors.
MATERIALS AND METHODS
Monolayer and RCCS cultures
KNS42 (pediatric GBM) [15] and Res196 [16] 
(pediatric ependymoma) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) / F12 (Invitrogen); 
U87 (adult GBM), T7 / 11 (adult primary GBM) and GB-1 
(pediatric mixed glial-neuronal grade III tumor, previously 
described by us) [17] in DMEM (Invitrogen); E14TG2A 
(mouse ESC) in Glasgow minimal essential medium 
(Sigma); HBMEC [18] (brain microvascular endothelial 
cells) in Roswell Park Memorial Institute (RPMI) medium 
1640 (Sigma); and post-natal day 9 mouse NSC with Oct4 
over-expression in B27 / N2 / DMEM / F12 neurobasal 
medium. NSC with the Oct4 transgene was generated 
as described [19]. All media were supplemented with 
10% fetal bovine serum (except HBMEC which was 
supplemented with 20% fetal bovine serum). A 1:1 
tumor:endothelial ratio media was used as co-culture 
media. 3D RCCS (Synthecon, Luxembourg) culture was 
commenced by introducing 1 x 106 cells as a single cell 
suspension into a 10 ml rotating vessel containing media as 
per monolayer cultures. Once a visible aggregate formed 
(typically by 1-2 days), revolution speed was adjusted 
to balance the Coriolis force against gravity in order to 
maintain the aggregate in stationary free-fall. Harvested 
aggregates (typically after 7-10 days) were either fixed 
in 4% paraformaldehyde or stored frozen at -80ºC until 
required for further analysis. Exposure to angiogenic 
inhibitors was achieved by culturing RCCS aggregates in 
media containing either 10 µM anti-vascular endothelial 
growth factor (VEGF) inhibitor (Calbiochem, CBO-P11) 
or 15 µM anti-fibroblast growth factor receptor (FGFR) 
inhibitor (Calbiochem, PD166866) for three days. KNS42 
and U87 hypoxic monolayer culture was achieved via a 24 
hour incubation period at 1% oxygen using a Glove Box 
Workstation (M.Braun, UK). For all subsequent molecular 
analyses, at least three independent RCCS aggregates 
were cultured and harvested. To determine the proportion 
of actively proliferating cells in glioma aggregates upon 
anti-angiogenic treatment, a Counter-Pen™ Cell Counter 
(VWR International, UK), was used to count Ki67 positive 
and Ki67 negative cells from three independent aggregates 
and using either a whole aggregate field of view or three 
different field of views for each aggregate. The mean +/- 
standard error (SEM) percentage of Ki67 positive cells 
relative to total number of cells was calculated.
Pediatric high-grade glioma tissue microarray
Pediatric high-grade gliomas (HGG) were surgically 
collected ante-mortem at UK pediatric neurosurgical 
centers (between 1987 and 2007) and banked by the 
Children’s Cancer Leukemia Group (UK CCLG) through 
Nottingham Children’s Brain Tumor Research Centre, 
with diagnosis confirmed by central pathological review. 
The project has ethics (UK ethics/R&D number PO 
059801 and OG 080002) and Biobank approval (11/




Standard immunohistochemistry procedure [20] 
was followed with the following antibody dilutions: 
anti-Ki67 (Dako, clone MiB-1), 1:50; anti-CD31 (Dako, 
clone JC70A), 1:50; anti-CD105 (Abcam, ab49679), 
1:100; anti-vWF, 1:800 (Abcam, ab6994). Standard 
immunofluorescence was followed with primary antibody 
dilutions of anti-CD31, anti-CD105 and anti-vWF as 
per immunohistochemistry; anti-GFAP (Abcam, ab726), 
1:1000; anti-HIF-2α (Abcam, ab199) 1:100 and secondary 
antibody combinations of Alexa488-conjugated goat anti-
rabbit, 1:200 and Alexa555-conjugated goat anti-mouse, 
1:200. Images were taken using a Nikon ECLIPSE 90i 
light microscope fitted with a Hamamatsu OCRA-ER 
camera using three fluorescent light filters. For KNS42 cell 
cultures undergoing Hypoxyprobe™ (Hypoxyprobe Inc., 
Burlington, MA) analysis, the Hypoxyprobe™ reagent 
(pimonidazole) was applied two hours before harvesting 
at 200 µM concentration. Samples were then fixed as 
standard and immunohistochemistry performed using the 
primary antibody supplied with the Hypoxyprobe™ kit at 
1:200 concentration. Three independent RCCS aggregates 
were fixed and sectioned prior to immunohistochemical 
detection and representative qualitative images taken from 
five slides.
Array quantitative reverse transcriptase (RT)-
PCR
cDNA was synthesized from 1 µg total RNA using 
the RT2 First Strand Kit (SABiosciences) according to 
the standard protocol. Array quantitative RT-PCR was 
performed using the human angiogenesis array (PAHS-
024D) (SABiosciences) containing 84 angiogenesis-
related genes and according to manufacturer guidelines 
using 96 well plates. The array was run on a CFX96 
(BioRad) instrument for 10 minutes at 95ºC followed by 
40 cycles of 95ºC for 15 seconds and 60ºC for one minute. 
Each cycle was followed by a plate read and CT values 
were calculated for each well in triplicate with each array 
experiment conducted on three independent aggregates or 
three independent monolayer cultures for each line. 
In vivo xenografts
Six nude mice were implanted subcutaneously in 
the flank with 1 x 106 U87 glioma cells. Tumors were 
harvested after four weeks growth, formalin fixed and 
paraffin embedded. Immunohistochemistry against 
human-specific vascular markers was undertaken in a 
standard fashion. All procedures were in compliance 
with the Animals (Scientific Procedures) Act 1986 with 
mice having access to sterile food and water ad libitum, 
environmental enrichment and ample sterile bedding.
Matrigel tubule formation assay
Endothelial-like tubule formation was assessed 
using the BioCoat Angiogenesis System (BD Biosciences). 
Briefly, 2 x 104 KNS42 cells were seeded onto Matrigel 
in each well of a 24-well plate using endothelial medium 
EBM-2 (Lonza) containing 10 ng / ml FGF and 25 ng / 
ml VEGF supplemented with either: VEGF inhibitor; 
FGFR inhibitor; both VEGF and FGFR inhibitors; 100 µg 
/ ml desferrioxamine (DFO) hypoxic inducer; or DMSO 
alone. Images of tubules were taken 48 hours post-seeding 
using a light microscope. Cells were plated in triplicate 
wells and the experiment repeated three times, with 
representative qualitative images taken. To semi-quantitate 
the degree of vessel-like formation, the number of fully-
formed structurally intact tubules, deemed as those with 
closed sides, were counted per well. The mean number of 
tubules +/- SEM was determined from triplicates of three 
independent experiments (n = 9). 
Biostatistics
Analysis of the array quantitative RT-PCR data 
was undertaken using the accompanying Excel based 
statistical package (SABiosciences) and confirmed using 
SPSS in order to determine significant fold changes. 
Gene expression data was presented consistently using 
volcano plots where fold-change was plotted directly 
against statistical significance. P-values were considered 
significant at less than 0.05 throughout. An independent 
student t-test (SPSS) was used to determine significant 
differences in vessel-like tubule formation in the Matrigel 
assay.
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